First 90 Days


  • Daniel Paterson, CEO, Verastem Oncology
    Image attribution tooltip
    Permission granted by Verastem
    Image attribution tooltip
    Q&A // First 90 Days

    With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition

    As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.

    By April 4, 2024
  • Dr. Juan Camilo Arjona Ferreira, chief medical officer, Organon
    Image attribution tooltip
    Permission granted by Organon
    Image attribution tooltip
    Q&A // First 90 Days

    Organon’s chief medical officer wants to change how the world sees women’s health

    Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.

    By Nov. 22, 2023
  • Growing plant in low poly wireframe style
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Why Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’

    The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.

    By Alexandra Pecci • Sept. 26, 2023
  • bullseye
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus

    After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.

    By Alexandra Pecci • July 11, 2023
  • Stethoscope , passport document, airplane and globe on a table.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    A BMS exec’s journey around the world in 90 days

    As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.

    By Karissa Waddick • July 5, 2023
  • Martine van Vugt, executive vice president and chief strategy officer, Genmab
    Image attribution tooltip
    Permission granted by Genmab
    Image attribution tooltip
    Q&A // First 90 Days

    From science to strategy, this exec is painting Genmab’s bigger picture into the next decade

    Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of "knock your socks off" antibodies.

    By May 2, 2023
  • Cell therapy DNA
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    The ‘recovering academic’ leading Allogene to the next stage of cell therapy

    Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.

    By March 2, 2023
  • Professional headshot of Brian Fox
    Image attribution tooltip
    Permission granted by Klick Group
    Image attribution tooltip
    Q&A // First 90 Days

    Brian Fox is bringing ‘fresh eyes’ to ad agency Klick

    Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.

    By Karissa Waddick • Feb. 13, 2023
  • Victoria Richon
    Image attribution tooltip
    Permission granted by Entact Bio
    Image attribution tooltip
    Q&A // First 90 Days

    Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

    Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.

    By Kelly Bilodeau • Feb. 6, 2023
  • arrow change
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Dr. Sy Pretorius, Eversana’s new COO, is flipping the script on his career

    With a long history in the clinical space, Pretorius is now applying those deep insights to the commercial side of the business.

    By Dec. 9, 2022
  • Subvariant virus spreading as viral pathogens
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

    President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

    By Kelly Bilodeau • Oct. 13, 2022
  • CFO
    Image attribution tooltip
    joel-t via Getty Images
    Image attribution tooltip
    First 90 Days

    First 90 Days: Adaptive Biotech’s Tycho Peterson

    A long-time analyst, Tycho Peterson brings his business savvy to the C-suite at Adaptive, where he began as CFO in June with a knowledge of what works and what doesn't in the diagnostics space.

    By Sept. 1, 2022
  • Brian Goff stands laughing in the forefront, with a crowded room of business attire-clad people in the background.
    Image attribution tooltip

    Permission granted by Brian Goff.

    Image attribution tooltip
    Q&A // First 90 Days

    First 90 Days: Agios Pharmaceuticals’ Brian Goff

    The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.

    By Alexandra Pecci • Aug. 22, 2022
  • gene therapy
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    Anjarium Biosciences’ CEO on its next-gen gene therapies

    Stephen Yoo aims to build on the buzz around the company’s leading-edge gene therapy tech.

    By Kim Ribbink • July 15, 2022
  • Editas Medicine CEO Gilmore O'Neill
    Image attribution tooltip
    Permission granted by Editas/Gilmore O'Neill
    Image attribution tooltip
    Q&A // First 90 Days

    First 90 Days: Editas Medicine’s Gilmore O’Neill

    The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.

    By June 13, 2022
  • David Jimenez
    Image attribution tooltip

    Permission granted by David Jimenez.

    Image attribution tooltip
    Q&A // First 90 Days

    First 90 Days: Janssen Immunology’s David Jimenez

    The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.

    By June 6, 2022
  • Sosei Heptares CEO Chris Cargill
    Image attribution tooltip
    Permission granted by Sosei Heptares/Chris Cargill
    Image attribution tooltip
    Q&A // First 90 Days

    First 90 Days: Sosei Heptares’ Chris Cargill

    The company’s new CEO is looking to drive growth through collaboration and transparency.

    By Kim Ribbink • May 31, 2022
  • CEO of Syneos Health
    Image attribution tooltip

    Permission granted by Michelle Keefe.

    Image attribution tooltip
    Q&A // First 90 Days

    First 90 Days: Syneos Health’s Michelle Keefe

    The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.

    By May 23, 2022
  • Image attribution tooltip
    Real Chemistry/PharmaMore
    Image attribution tooltip
    Q&A

    Lessons from improv: Shankar Narayanan’s ‘yes, and’ approach to healthcare leadership

    Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.

    By April 4, 2022
  • Image attribution tooltip
    Retrieved from PharmaVOICE on March 21, 2022
    Image attribution tooltip
    Q&A

    BioMarin’s new global head of advocacy is tackling the holy grail of patient engagement

    In her new role, Dr. Roz is keeping her patient-first approach.

    By March 21, 2022
  • headshot
    Image attribution tooltip
    Permission granted by Peter Anastasiou
    Image attribution tooltip
    Q&A // First 90 Days

    New Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality

    Read what Capsida CEO Peter Anastasiou has planned for his new role.

    By Feb. 3, 2022